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Abstract
The Czech Republic has one of the highest incidences of colorectal cancer (CRC) in Europe. To evaluate whether sporadic
CRCs in Czech patients have specific mutational profiles we analysed somatic genetic changes in known CRC genes (APC,
KRAS, TP53, CTNNB1, MUTYH and BRAF, loss of heterozygosity (LOH) at the APC locus, microsatellite instability (MSI), and
methylation of the MLH1 promoter) in 103 tumours from 102 individuals. The most frequently mutated gene was APC
(68.9% of tumours), followed by KRAS (31.1%), TP53 (27.2%), BRAF (8.7%) and CTNNB1 (1.9%). Heterozygous germline MUTYH
mutations in 2 patients were unlikely to contribute to the development of their CRCs. LOH at the APC locus was found in
34.3% of tumours, MSI in 24.3% and MLH1 methylation in 12.7%. Seven tumours (6.9%) were without any changes in the
genes tested. The analysis yielded several findings possibly specific for the Czech cohort. Somatic APC mutations did not
cluster in the mutation cluster region (MCR). Tumours with MSI but no MLH1 methylation showed earlier onset and more
severe mutational profiles compared to MSI tumours with MLH1 methylation. TP53 mutations were predominantly located
outside the hot spots, and transitions were underrepresented. Our analysis supports the observation that germline MUTYH
mutations are rare in Czech individuals with sporadic CRCs. Our findings suggest the influence of specific ethnic genetic
factors and/or lifestyle and dietary habits typical for the Czech population on the development of these cancers.
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Introduction
Colorectal cancer (CRC) is the second most common form of
cancer in Europe, and the Czech Republic has the second highest
CRC incidence and mortality among 38 European countries [1].
The reasons for this are unknown and can include both genetic
and environmental factors. Hereditary cancer susceptibility syn-
dromes account for no more than 5% of CRC cases [2]. The
major autosomal dominant disorders with a high risk of CRC
include Lynch syndrome (hereditary non-polyposis colorectal
cancer, HNPCC), familial adenomatous polyposis (FAP), Peutz-
Jeghers syndrome (PJS) and juvenile polyposis (JP) [3]. MUTYH
associated polyposis (MAP) is an autosomal recessive hereditary
CRC predisposition [4]. The incidence of germline MUTYH
mutations in Czech FAP negative sporadic CRC patients is lower
compared to other European countries [5,6], and there seems to
be no increased incidence of the autosomal dominant forms either.
About 75% CRCs are sporadic, occurring in individuals with no
remarkable family history of the disease. Dietary and other
lifestyle-related and environmental factors are supposed to play an
important role in the aetiology of this form of CRC. Sporadic
CRCs have even more biological variables compared to hereditary
CRCs. Most sporadic CRCs have mutations in the APC gene [7],
and an increased rate of G:C.T:A transversions in APC can also
reveal ‘‘hidden’’ MAP patients [4]. Similarly defects in several
other pathways result in other specific mutation signatures [8].
APC negative tumours can carry CTNNB1 gene mutations [9,10].
The mutation status of the KRAS and TP53 genes, two other key
players in CRC [11], can reflect carcinogen exposure and reveal
the tumour aetiology [12]. Microsatellite instability (MSI) is found
in about 15-20% of CRCs; 3-5% are associated with Lynch
syndrome and the remaining are sporadic [13]. MSI is associated
with MLH1 promoter methylation, somatic BRAF mutations, and
has an inverse relationship with APC mutations [14,15]. Thus, the
molecular genetic landscape of CRC is rather complex. However,
its exploration is a prerequisite for personalized molecular
medicine and identification of biomarkers for early detection of
tumours, risk stratification, prognosis and prediction of treatment
responses [16].
The aim of our study was to contribute to the understanding of
CRC tumorigenesis by the analysis of most genes known to be
implicated in CRC, and by correlating the molecular genetic
profiles of the tumours with their clinical and histopathological
data. We also focused on the molecular genetic features of the
Czech CRC patients, because we hypothesized that their high
incidence and mortality could be accompanied by specific muta-
tion profiles, which could reflect possible specific ethnic, geo-
graphical, dietary or lifestyle factors. To this aim we analysed the
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(LOH) at the APC locus, the CTNNB1, MUTYH, KRAS and TP53
genes, as well as MSI, methylation status of the MLH1 promoter,
and BRAF mutations in CRCs from 102 Czech patients.
Materials and Methods
Ethics Statement
The study was based on informed consent and approval of the
local ethics committee.
Patients
The samples were obtained from unselected consecutive patients
who had undergone curative surgical resection for primary
colorectal cancer at the Department of Surgery, University Hospital
Motol, Prague, Czech Republic. Because of our focus on sporadic
CRC patients, we excluded individuals with family history of CRC
disease and/or presence of polyps. Also excluded were patients who
received preoperative radiotherapy, patients with low quality of the
DNA sample, and patients in whom no matching mucosa sample
was available. Finally 103 tumours and matching normal tissues
were collected from 102 CRC patients (51 males and 51 females,
age at tumour onset 13-86 years, median 64 years) at the Depar-
tment of Surgery, University Hospital Motol, Prague, Czech
Republic. Fifty-six patients were from Prague and the rest were
from all regions of the Czech Republic. All tumours were fresh-
frozen at -70uC at colectomy. A minimum of 85% of neoplastic
tissue was present in each resected sample as assessed by a
pathologist. The characteristics of the patients and clinical and
histopathological features of their tumours are shown in Table S1.
Mutation analysis
DNA was prepared using the Genomic DNA Purification Kit
(Gentra Systems, Minneapolis, MI, USA) according to the
manufacturer instructions. APC exons 1-15, TP53 exons 2-10,
CTNNB1 exon 3 and KRAS exons 1-2 were amplified in PCR
reactions containing 20 mM Tris-HCl (pH 8.0), 1 mM DTT,
0.1 mM EDTA, 100 mM KCl, 0.5% (v/v) Nonidet P40, 0.5% (v/
v) Tween 20, 50% (v/v) glycerol, 200 mM dNTPs, 1 U of Taq
Polymerase (Fermentas, Glen Burnie, MD, USA), 3 pmol of each
primer, 1 ml of 10x LCGreen Plus Dye (Idaho Technology, Salt
Lake City, UT, USA) and 20 ng of DNA in a total volume of 10 ml
for 1 min at 95uC, 45 cycles of 1 min at 95uC, 30 s annealing, 30 s
at 72uC, and then 7 min at 72uC. Heteroduplexes were formed by
heating the PCR products to 95uC for 2 min and cooling down to
4uC, and subjected to high resolution melting (HRM) analysis
using LightScanner (Idaho Technology). BRAF exon 15 and
MUTYH exons 6-8, 12 and 13-14 were sequenced directly from
PCR amplicons prepared as above but with 10 pmol of each
primer, no dye, in a total volume of 30 ml for 1 min at 95uC, 32
cycles of 1 min at 95uC, 1 min annealing, 1 min at 72uC, and then
7 min at 72uC. Annealing temperatures, MgCl2 concentrations
and primer sequences are available upon request. PCR products
with suspected variations identified by HRM were purified using
the SureClean PCR purification kit (Bioline, London, UK) and
sequenced in both directions using the BigDye Terminator v3.1
Cycle Sequencing kit on an ABI 3130 Genetic Analyser (Applied
Biosystems, Foster City, CA, USA). Somatic mutations found in
tumours were also analysed in the corresponding mucosa to assess
their germline status. The functional impact of APC mutations was
predicted using Polyphen [17]. Bioinformatic analysis also used
the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/snp),
the UMD p53 Mutation Database (UMD, http://p53.free.fr/
Database/p53_database.html, The p53 Handbook 2.0), and the
Leiden Open Variation Database (LOVD, v.2.0 Build 29, http://
www.insight-group.org/mutations/). In tumours with 2 or more
APC mutations separated by a distance of #5 kb the phase of the
mutations was analysed using allele-specific PCR and sequencing.
The primer sequences are available upon request.
LOH analysis
LOH at the APC locus was tested using the microsatellite marker
D5S346 and capillary electrophoresis on an ABI 3130 Genetic
Analyser. Allelic loss was scored if the area under one allelic peak in
the tumour was reduced by 50% or more relative to the other allele,
after correcting for the ratio of allelic peak areas in normal DNA.
Samples with constitutional homozygosity at D5S346 or showing
MSI in tumours were scored as non-informative.
MSI analysis
MSI was assessed at five microsatellite loci (Bat-25, Bat-26,
D2S123, D5S346, and D17S250) as described previously [18].
Matching normal and tumour DNA samples were compared, and
tumours showing instability at one locus were scored as MSI-low
(MSI-L), at two or more loci as MSI-high (MSI-H).
DNA methylation assay
DNA methylation of the MLH1 promoter was analysed using
methylation specific multiplex ligation-dependent probe amplifi-
cation (MS-MLPA). SALSA MS-MLPA Kit ME011-A1 (MRC-
Holland, Amsterdam, The Netherlands) with 6 probes in the
MLH1 gene was used according to the manufacturer instructions.
PCR products were analysed using an ABI 3130 Genetic Analyser.
Data analysis was performed with the Genemapper and Coffalyser
software (Applied Biosystems and MRC-Holland, respectively).
The relative peak area of the signal from a specific probe was
calculated by dividing the peak area by the combined areas of
peaks of the control probes and multiplying the value by 100. The
relative peak areas of probes from the Hha I digested sample were
compared with those from the corresponding undigested sample,
giving the percentage ratio of methylation at CpG sites. The cut-
off value for aberrant methylation was set to 25% or higher.
Immunohistochemistry (IHC)
A portion of each tissue sample was formalin fixed, embedded in
paraffin and processed using standard histopathologic procedures.
Representative blocks containing enough of tumour and normal
tissue were cut to 4 mm sections, deparaffinised and rehydrated.
Target Retrieval Solution, High pH (DakoCytomation, Glostrup,
Denmark) was used for epitope retrieval at 96uC for 30 min. The
sections were incubated overnight at 4uC with primary monoclo-
nal mouse anti-human MLH1 and MSH2 antibodies (clones G168-
15 and G219-1129, BD Biosciences, NJ, USA) diluted 1:100. The
MLH1 antibody complexes were visualized using the streptavidin-
biotin detection kit LSAB+, Dako REAL Detection Systems,
HRP/DAB+, Rabbit/Mouse (DakoCytomation) and 3,39-diami-
nobenzidin tetrahydrochlorid (DAB, Fluka Chemie, Buchs,
Switzerland). The MSH2 antibody complexes were localised using
N-Histofine Simple Stain MAX PO (MULTI) (Nichirei Biosci-
ences, Tokyo, Japan) and DAB. All sections were stained with
hematoxylin, dehydrated and mounted. Nuclear staining only was
considered for both antibodies, and the normal tissue in the same
section was used as an internal positive control. Only cases with
complete negativity of all tumour cells and positivity of the internal
control were interpreted as negative and suspicious of MLH1 or
MSH2 gene dysfunction. This IHC analysis was performed in 39
tumours (see Table S1).
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Statistical analyses were carried out using GraphPad InStat 3.10
(GraphPad Software, La Jolla, CA, USA) and IBM SPSS Statistics
version 18(IBM Corporation,NewYork, USA).Fisher’sexact,Chi-
square or Exhaustive CHAID tests were used where appropriate.
All P values were two-tailed, and P values less than 0.05 were
considered statistically significant. Mutations of the genes tested and
their combinations, LOH, MSI and MLH1 promoter methylation
were correlated with age at tumour onset, gender, location of the
tumour, and its histopathological characteristics.
Results
Details of mutation profiles, LOH, MSI, DNA methylation and
IHC of individual tumours are shown in Table S1.
Distribution of genetic defects in tumours
Tumours were scored as APC mutated if they carried at least
one clearly deleterious APC mutation (mutations leading to
premature termination and missense mutations found in CRC
but not in the corresponding mucosa, absent from dbSNP and
predicted to be pathogenic - a total of 103 mutations). Overall, 71
tumours (68.9%) had the APC gene mutated (Table 1): 45 CRCs
had 1 deleterious mutation, 23 had 2 mutations, 2 had 3 mutations
and 1 had 6 mutations. Seven additional tumours (6.8%) showed
no mutation but had LOH at the APC locus. Twenty tumours had
neither a mutation nor LOH. The remaining 5 non-mutated
tumours were not informative. Three missense APC variants
(R382S, N813S and A1366V) were absent from mucosa and
dbSNP but were predicted to be benign, totalling the number of
somatic APC variants observed to 106.
LOH at the APC locus was found in 35 of 90 informative
tumours (38.9%). Of 63 informative tumours with the APC gene
mutated, 28 had LOH at the APC locus (44.4%). Of 43 tumours
with only one deleterious APC mutation, 27 had LOH (62.8%),
while of 20 tumours with 2 and more mutations, only 1 had LOH
(5%, P,0.0001). Mutant allele specific amplification was possible
in 12 of 26 tumours with 2 and more APC mutations to show their
phase. Fourteen other samples could not be assessed due to a large
distance between the mutations ($10 kb, 10 tumours; $5 kb, 4
tumours). In all 12 tumours tested the mutations were in trans
configuration. Out of the 27 tumours with LOH and one APC
Table 1. Numbers of tumours with genetic defects studied.
(n) APC mutated KRAS mutated TP53 mutated BRAF mutated CTNNB1 mutated with MLH1 methylation with MSI
(%) (%) (%) (%) (%) (%) (%)
all CRC (103) 71 32 28 9 2 13 25
(68.9) (31.1) (27.2) (8.7) (1.9) (12.6) (24.3)
Sex of the patient
CRC in females (51) 36 14 15 4 1 7 11
(70.6) (27.5) (29.4) (7.8) (2) (13.7) (21.6)
CRC in males (52) 35 18 13 5 1 6 14
(67.3) (34.6) (25) (9.6) (1.9) (11.5) (26.9)
Tumour location
proximal CRC (43) 26 10 7* 7* 0 13** 21**
(60.5) (23.3) (16.3) (14.9) (0) (30.2) (48.8)
distal CRC (60) 45 22 21* 2* 2 0** 4**
(75) (36.7) (35) (3.3) (3.3) (0) (6.7)
Tumour stage
I (18) 14 5 7 1 0 1 4
(77.8) (27.8) (38.9) (5.6) (0) (5.6) (22.2)
II (38) 24 12 2 5 0 9 14
(63.2) (31.6) (5.3) (13.2) (0) (23.7) (36.8)
III (32) 23 8 12 2 2 2 4
(71.9) (25) (37.5) (6.3) (6.3) (6.3) (12.5)
I V ( 1 2 ) 7451 0 1 2
(58.3) (33.3) (41.7) (8.3) (0) (8.3) (16.7)
n . a . ( 3 ) 3320 0 0 1
Lymphatic invasion
0 (56) 38 17 9* 6 0 10 18
(67.9) (30.4) (16.1) (10.7) (0) (17.9) (32.1)
I+II (43) 29 11 17* 3 2 3 6
(67.4) (25.6) (39.5) (7) (4.7) (7) (14)
n . a . ( 4 ) 4420 0 0 1
n.a., information not available; * significant (P,0.05); ** significant (P,0.0001, Fisher’s exact).
doi:10.1371/journal.pone.0024114.t001
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signal intensity of the mutated and wildtype alleles, 6 had LOH of
the mutant allele and 6 cases could not be unequivocally resolved.
However, any admixture of normal mucosa can partly mask the
LOH of the wildtype allele.
TP53 mutations were considered deleterious if they were absent
from mucosa and dbSNP, and were not listed as polymorphisms in
UMD. Tumours with any variation in codons 12, 13 or 61 of
KRAS and in exon 15 of BRAF were classified as mutated. In
contrast to APC, no tumours contained more than one mutation in
any of these 3 genes. Simultaneous occurrence of mutations in the
APC, TP53, KRAS and BRAF genes is shown in Figure 1. The most
common combination of mutated genes was APC and KRAS
(35.6%), APC and TP53 (31.1%), whereas no tumours had
mutations in TP53 and KRAS only. BRAF mutations were mutually
exclusive with KRAS mutations, and four BRAF mutations were
found in tumours with MSI. Fifteen tumours lacked mutations in
any of these 4 genes; however, 3 of them had LOH in APC. Of the
remaining 12 tumours, 2 were not informative for LOH and 10
were lacking any detectable defect in these 4 genes.
Only 2 tumours had mutations in the CTNNB1 gene. One of
them was the tumour with 6 deleterious APC mutations mentioned
above. No other mutations or LOH were found in the two
CTNNB1 mutated tumours. Two other CRCs carried heterozy-
gous MUTYH mutations which were also present in the mucosa,
thus excluding the presence of MAP patients in our cohort.
MSI was found in 25 tumours (24.3%), out of which MSI-H in
21 cases (20.4%) and MSI-L in 4 cases (3.9%). Twelve tumours
with MSI (all MSI-H) had the MLH1 promoter methylated. None
of the patients with a MSI tumour had a relative with a HNPCC-
related cancer. Thirteen MSI tumours without MLH1 methylation
displayed more severe mutation profiles (11 had an APC defect, 4
KRAS,2CTNNB1 and 3 TP53 mutations, and only 1 showed no
other genetic defect than MSI). This contrasted to 12 tumours
with MSI and MLH1 methylation, of which 7 had no other genetic
defect or a BRAF mutation (P=0.0099). Six of 9 BRAF mutated
tumours showed MSI, and all of those had the MLH1 promoter
methylated and were proximally located.
Mutation spectra
Considering all 106 variants found in APC, point substitutions
(46 nonsense, 9 missense and 3 splice, 54.7%) were slightly more
frequent than frameshift (FS) mutations (29 deletions, 18
insertions/duplications and 1 indel, 45.3%, Figure 2). However,
in the mutation cluster region (MCR) [7], FS mutations occurred
more often than point substitutions (34 FS (64.2%) and 19 point
substitutions (35.8%) out of the total of 53 mutations in MCR,
P=0.0003, Figure 2). Of the total of 31 APC mutations in MSI
tumours, 15 were FS (48.4%) and 16 point substitutions (51.6%).
This was similar to tumours without MSI, where out of the total of
72 mutations 33 were FS (45.8%) and 39 point substitutions
(54.2%, P=0.8326).
Of 28 TP53 mutations observed, 15 (53.6%) were missense and
13 (46.4%) were FS and nonsense, which was significantly different
from CRC mutations listed in UMD, where missense mutations
were highly predominant (81% missense, 19% FS and nonsense,
P=0.0005, X
2 test). TP53 mutations were located in exons 4-10,
with 64% of them in exons 5-8. Interestingly, only 1 TP53
mutation (4%) belonged to the 10 most common CRC mutations
listed in UMD, where out of 3584 mutations 1566 (43.7%) were in
these hotspots (P=0.004, X
2 test, Figure 3). Compared to UMD,
we could observe less G:C.A:T but more G:C.C:G, G:C.T:A
and FS events (Figure 4).
The majority of KRAS mutations, 23 (71.9%), were found in
codon 12. Codons 13 and 61 were involved in 5 (15.6%) and 4
(12.5%) tumours, respectively. The most common substitution was
G.A (16, 50%), G.T (11, 34.4%) and A.C (3, 9.4%), while
G.C and A.T substitutions were present once each (3.1%).
No difference in tumour spectra was observed between males
and females (Table S1).
Correlation of molecular findings with clinical and IHC
data
APC and KRAS mutations did not show any significant cor-
relation with tumour location, stage, grade and lymph node in-
volvement, age at onset or sex of the patient (Table S1). BRAF
Figure 1. Distribution of mutations in selected genes. Mutational events in the APC, TP53, KRAS and BRAF genes dispersed in 103 tumours
studied. Nineteen tumours carried no mutations in these genes.
a this group includes 1 tumour with a CTNNB1 mutation;
b this group includes 1
tumour with a germline MUTYH mutation;
c this group includes 1 tumour with 8 point substitutions in APC.
doi:10.1371/journal.pone.0024114.g001
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proximal (19.4%) and 2 of 58 distal (3.5%) tumours were mutated
(P=0.0323). TP53 mutations were more frequent in distal
tumours: 21 of 60 distal tumours (35.0%) were mutated compared
to only 7 of 43 proximal tumours (16.3%, P=0.0440), and in
invading tumours: 17 of 43 invading tumours (39.5%) were
mutated compared to only 9 of 56 non-invading tumours (16.1%,
P=0.0114, 4 tumours lacked information). Exhaustive CHAID
test revealed that tumours with TP53 mutations had a tendency to
skip stage II or progress through it very quickly to stage III
(P=0.002, Figure 5).
The number of CTNNB1 mutated tumours was too low for any
correlation. Both were in distal colon and showed lymphatic
invasion. Concerning MUTYH, one mutation carrier was an 83
year old woman with stage II, grade 2, proximally localized CRC
without lymphatic invasion and MSI but with 2 FS APC mutations
and one splice TP53 mutation. The other MUTYH mutation
carrier was a 58 year old man with proximally localized stage III,
grade 3 CRC, with no lymphatic invasion, showing MSI-H and
MLH1 methylation but no other genetic defects.
Both MSI and MLH1 promoter methylation were significantly
more frequent in proximal tumours (MSI in 21 of 43 proximal
tumours but only in 4 of 60 distal tumours, P=,0.0001; MLH1
methylation in 13 of 30 proximal tumours but in none of 60 distal
tumours, P=,0.0001, Table 1). The mean age at tumour onset
was similar in patients with and without MSI (62.7 and 64.7 years,
respectively, P=0.4723). However, the mean age at onset in 13
patients with MSI without MLH1 methylation was lower (58.2
years) compared to that in 12 patients with MSI and MLH1
methylation (67.6 years, P=0.0894). The tumour stage was
comparable in both groups. The tumour grade was predominantly
I+II in the first group and III in the second (P=0.0820).
Figure 2. Comparison of the type of mutations in the APC gene. Light grey, frameshift mutations; dark grey, point substitutions. Frameshift
mutations were more frequent in MCR while point substitutions, especially C.T resulting in Arg.STOP, were more common outside the MCR.
doi:10.1371/journal.pone.0024114.g002
Figure 3. Comparison of the distribution of mutations along the TP53 coding region. TP53 mutations in CRCs from the UMD database (top)
and in our sample (bottom) are depicted. The length of the bars reflects the number of mutations. Seven hot spot positions (representing 10 most
common substitutions in UMD) are indicated by codon numbers. Numbers in frames indicates two different frequent substitutions at the same
position. In our sample, two different point substitutions were observed in codon 245, and only one of them belonged to the 10 hot spot variants.
Asterisks indicate FS mutations in our cohort.
doi:10.1371/journal.pone.0024114.g003
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We analysed mutation profiles in sporadic CRCs of Czech
patients, in whom CRC incidence and mortality is one of the
highest in Europe and is still increasing [1,19].
APC mutations are the key player in CRC tumorigenesis.
However, mutation analysis of the APC gene is time-consuming
and expensive, and is often limited to MCR which covers about
10% of the APC coding region [7]. In several studies where the
entire gene was sequenced the frequency of mutations in CRCs
was 60% [15,20], similar to our results (68.9%). If we restricted
our analysis to MCR only, we would miss 59 mutations (55.6%)
including 33 mutations in 26 tumours (25.2%) which would be
classified as non-mutated. Some reports indicated an interdepen-
dence of two hits in APC both in sporadic and in FAP associated
CRCs: APC mutations in the MCR were predominantly associated
withLOHwhilemutationsoutsidetheMCR withanothermutation
[21,22]. In our cohort, mutations in the MCR and outside the
MCR were equally associated with LOH, and many mutations
outside the MCR were coupled with at least one mutation in the
MCR. Point substitutions occurred more often outside the MCR
compared to FS mutations (Figure 2), and commonly included
C.T transitions at CpG sites mainly changing arginine codons to
STOP as reported previously [15,20]. The frequency of APC defects
rose to 75.7% if LOH at the APC locus was included (7 of our CRCs
had LOH only). LOH at the APC locus was reported in 30-40% of
CRCs [22], similarly to our results (35%). Significantly increased
LOH in our tumours with just 1 somatic APC mutation, the trans
position of 2 pathogenic APC mutations confirmed in tumours
where the mutation phase was tested, and preferential loss of the
wildtype allele in tumours with LOH and an APC mutation support
the two-hit model.
CRCswithintactAPCmaycarrymutationsinCTNNB1,acritical
downstream gene of the WNT signalling pathway [23], although
these are rather rare in sporadic CRCs [9,10]. CTNNB1 mutations
may be more frequent in MSI-H tumours [9]. Both our tumours
with CTNNB1 mutations were MSI-H. One carried p.S45F, a likely
activating mutation located in one of the hotspots and supposed to
deregulate the WNT signalling instead of APC. Indeed, this tumour
carried no APC mutation. The other CRC had the p.A20V
mutation, which is not located in any of the critical sites, does not
change amino acid polarity and may not be disease-causing. This
tumour had several inactivating APC mutations.
Germline MUTYH mutations have lower incidence in the
Czech Republic [5,6]. The frequency of biallelic carriers of 2 most
prevalent Caucasian mutations, p.Y179C and p.G396D, among
Figure 4. Mutational events in the TP53 gene. Mutations found in CRCs listed in the UMD database (left) and observed in our CRCs (right). The
CRCs of Czech patients had more frameshift mutations and transversions, while transitions, especially at CpG sites, were less frequent.
doi:10.1371/journal.pone.0024114.g004
Figure 5. Comparison of the stage of tumours without and with TP53 mutations. White, stage I; light grey, stage II; dark grey, stage III; black,
stage IV. Segments show the number and percentage of tumours (3 tumours lacked information). Tumours with TP53 mutations may have a
tendency to skip stage II or progress through it very quickly compared to tumours without TP53 mutations (P=0.002).
doi:10.1371/journal.pone.0024114.g005
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frequency of carriers of monoallelic MUTYH mutations among
CRC patients was 0.9-4.2% [5]. Cases of biallelic MUTYH
carriers with sporadic CRC without polyps are rare [24], and our
study included primarily individuals without polyps. Of the
monoallelic MUTYH mutations observed in our patients, the
p.R182H mutation is pathogenic [25], while p.Q479L is of an
unknown effect. An elevated risk of CRC was proposed for carriers
of monoallelic MUTYH mutations [26], but two large studies did
not confirm this conviction [27,28]. A retrospective analysis of
pathological reports revealed 3 diminutive tubulovillous adenomas
with moderate dysplasia in the carrier of the first mutation.
However, neither of the 2 CRCs in our patients had the
characteristic mutation profile [4], and therefore they were not
likely caused by the germline MUTYH mutations.
In addition to "hidden" MAP patients the mutation analysis of
the whole APC gene could also reveal other specific mutation
profiles typical for Czech patients. We identified a remarkable
patient with 8 somatic variants in the APC gene. Two of these
point variants were nonsense, two splice, three missense (one of
them predicted to be benign) and one silent, and, interestingly, the
tumour was MSI-H. The patient was analysed in detail and the
results will be published separately (manuscript in preparation).
MSI can be detected in up to 15% of sporadic CRCs and in
almost all HNPCC-associated CRCs. While MSI in HNPCC
tumours is caused by germline mutations in mismatch repair
(MMR) genes, MSI in sporadic tumours is often associated with
MLH1 promoter methylation and accompanied by somatic BRAF
mutations [14]. These changes were rarely if ever seen in HNPCC
tumours, and may be mutually exclusive with KRAS mutations
[29]. In our sample 24% of tumours showed MSI. This higher
incidence can be explained by the exclusion of rectal tumours with
neoadjuvant therapy that biased the distribution towards proximal
tumours where the MSI frequency is higher [30]. Similarly also
the exclusion of tumours with no available matching mucosa
might have biased the sample against aggressive and rectal
cancers. In our cohort the frequency of MLH1 promoter methy-
lation decreased with the distance of the tumour from caecum, and
was completely absent in tumours of the distal colon (Table S1).
Rare MLH1 promoter methylation in rectal cancers was described
in one study, but it was accompanied by high rate of MMR
protein deficiency, possibly due to the inclusion of Lynch-
associated tumours [31]. The rectal MSI-H tumours had worse
prognosis compared to those without MSI, which could be caused
by pre-operative irradiation or chemotherapy which had no effect
or might even be harmful for MSI-H cancer patients [31]. In
another study, distal MSI CRCs had lower incidence of MLH1
methylation and worse prognosis compared to proximal MSI
CRCs [32]. Our data suggest that proximal CRCs without MLH1
methylation could have similar clinicopathological and molecular
features as distal CRCs. Although we did not perform IHC
analysis of all MMR proteins in all MSI tumours and therefore
cannot exclude germline mutations in these genes, we suppose that
tumours without MLH1 methylation represent a different
subgroup. The reason for the uneven localization of the MSI
tumours, differential MLH1 promoter methylation and earlier
onset of MSI CRCs without MLH1 methylation is unknown and
can be caused by dietary habits, different environment (e.g.
varying pH) in different parts of the colon, different genes involved
or the combination of all of the above.
Our data confirmed the notion that BRAF mutations are
frequently found in sporadic MSI tumours [29], and support the
previous observation of BRAF mutations in about 5% of CRCs
without MSI [29,33]. In accordance with other reports [34,35], we
have found the inverse association between BRAF and APC
mutations. Six of 9 tumours with a BRAF mutation had no somatic
APC mutation. None of these 9 tumours had a KRAS mutation
either, which is in accord with others [33,34]. We did not observe
any differences in clinicopathological features of these tumours.
MMR deficiency, irrespective of its genetic or epigenetic origin,
leads to the mutator phenotype, and FS APC mutations, pre-
dominantly in mononucleotide tracks, are more frequent in MSI
tumours [36]. The mutational spectrum of our MSI tumours was
not different from that in tumours without MSI, but FS mutations
were more frequent in proximal MSI tumours without MLH1
promoter methylation.
The increased incidence of CRC in the Czech Republic can be
partly explained by the joint effect of elevated smoking prevalence
and obesity [19,37]. Mutation signatures in TP53 can reflect DNA
damage induced by specific carcinogens, ethnicity or lifestyle
habits [12]. For example, exposure to ultraviolet light is correlated
with TP53 transitions at dipyrimidine sites (CC.TT) [12];
aflatoxin B1 exposure with G:C.T:A transversions in codon 249
in hepatocellular carcinoma; and exposure to cigarette smoke with
G:C.T:A transversions in lung carcinoma [12]. TP53 mutations
observed in our sample included very few hotspot codons, and
their pattern and distribution was distinct from that of CRC
mutations listed in UMD (Figures 3, 4). Czech CRC patients have
less G:C.A:T transitions and more FS, G:C.C:G and G:C.T:A
events, although no predominant mutational event or specific hot
spot can be observed. These mutations are caused by polycyclic
aromatic hydrocarbons (PAHs) [38,39]. One of the main sources
of PAHs except tobacco smoke and environmental pollutants is
high-fat diet rich for smoked red meat [40]. PAHs are formed on
the surface of meat at high temperatures [41]. Home production
of smoked food and high consumption of red meat products is
characteristic of Czech households, especially in rural areas [42]. It
remains to be verified on a larger set of CRCs if these dietary
habits are the cause of the TP53 mutation signature observed.
Another explanation could involve population differences in the
frequency of functional polymorphisms in DNA repair genes,
which could modify the risk of CRC [43]. Further research is
needed to address this scenario.
Frequency and spectrum of KRAS and APC mutations did not
differ compared to most other reports. This could be partly
explained by the nature of mutations in these genes and their
ability to give the cell a growth advantage leading to positive clonal
selection. Only KRAS mutations in codons 12, 13, and 61 and
nonsense APC mutations are considered to give such advantage,
and therefore the investigation of mutational spectra of these genes
is of limited use [44].
No tumours had concurrent TP53 and KRAS mutations in
context of non-mutated APC (Figure 1). Similar findings were
noted in 2 other studies [15,45]. Concurrent TP53 and KRAS
mutations could be disadvantageous for tumour progression and
may arise only on the APC mutation background.
Nowadays two main independent molecular pathways of
colorectal tumorigenesis have been proposed: the conventional
adenoma-carcinoma pathway characterised with the initial
inactivation of the APC gene, accumulation of mutations in other
genes and chromosomal instability [46]; and the serrated pathway
with microsatellite instability, a relatively high frequency of BRAF
mutations and increased level of DNA methylation [47]. Although
most of CRCs could be clearly classified into one of these
pathways, they overlap and the mutational profile of a CRC may
show evidence of both. Thus, the classification of many tumours
remains ambiguous, e.g. of MSI tumours without MLH1 promoter
methylation but with severe mutational profiles and earlier onset
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here and elsewhere [31,32]. Although we cannot exclude the
possibility that among 13 MSI tumours from our cohort without
MLH1 promoter hypermethylation there may be a hidden Lynch
associated tumour, the selection criteria and the relatively low
percentage of true Lynch tumours among unselected CRCs [48]
stand against it.
There is an increasing effort to assess individual specific
molecular alterations for personalized diagnosis, prognosis and/or
treatment. As can be seen from our results, tumours with mutations
in multiple genes often had better staging or grading compared to
tumours with no or only very few genetic defects. This implies that
focusing on a single gene or defect or interpretation of the findings
using too simple rules may be misleading. Systematic sequencing of
cancer genomes reveals the diversity of cancer as to the number and
pattern of mutations arising probably due to DNA repair defects,
mutagenic exposure and cellular metabolism [49]. It has been
shown that a single CRC can harbour up to 76 point mutations and
9 copy number changes, and that rather whole pathways than
individual genes govern the process of carcinogenesis [50,51]. High-
throughput methods like next-generation sequencing or copy
number variation arrays can therefore be more helpful in managing
cancer patients.
In summary, the molecular genetic analysis of CRCs in Czech
patients confirmed the data from other studies but also yielded
potentially novel findings. First, MSI tumours with unmethylated
MLH1 promoter have earlier onset and more severe mutational
phenotype. Second, the Czech pattern and distribution of TP53
mutations differ significantly from published data. Third, muta-
tional analysis of the whole coding region of the APC gene
significantly increases the yield of the analysis, but did not pinpoint
any MAP patient, confirming that germline MUTYH mutations
are rare in the Czech population.
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